Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and pp242

lapatinib has been researched along with pp242 in 3 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(pp242)		Trials
(pp242)		Recent Studies (post-2010) (pp242)
1,9193051,442102098

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)pp242 (IC50)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)1.8085
Tyrosine-protein kinase ABL1Homo sapiens (human)2.502
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)2.6263
Epidermal growth factor receptorHomo sapiens (human)4.4
Tyrosine-protein kinase HCKHomo sapiens (human)2.4678
Platelet-derived growth factor receptor betaHomo sapiens (human)2.6263
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)2.49
Vascular endothelial growth factor receptor 2Homo sapiens (human)2.5011
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)1.9352
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)1.174
Serine/threonine-protein kinase mTORHomo sapiens (human)1.4284
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)1.3
Ephrin type-B receptor 4Homo sapiens (human)2.7122
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)1.8292
Receptor protein-tyrosine kinase Homo sapiens (human)2.6263
Rapamycin-insensitive companion of mTORHomo sapiens (human)0.08
Regulatory-associated protein of mTORHomo sapiens (human)0.008
Target of rapamycin complex 2 subunit MAPKAP1Homo sapiens (human)0.08
Target of rapamycin complex subunit LST8Homo sapiens (human)0.044
Phosphatidylinositol 4-kinase betaHomo sapiens (human)0.408

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Becker, MN; Copland, JA; Kreinest, PA; Marlow, LA; Vonroemeling, CA; Williams, CR; Wu, KJ1
Amin, DN; Gulizia, N; Moasser, MM; Ruiz-Saenz, A1

Other Studies

3 other study(ies) available for lapatinib and pp242

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.
    Urologic oncology, 2014, Volume: 32, Issue:3

    Topics: Aged; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Indoles; Lapatinib; Male; Purines; Quinazolines; Tissue Array Analysis; TOR Serine-Threonine Kinases; Triazines; Urinary Bladder Neoplasms

2014
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
    Oncotarget, 2015, Dec-01, Volume: 6, Issue:38

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Imidazoles; Indoles; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2015